“Rising Utilization of Targeted Therapies”
The global extramammary Paget disease (EMPD) market is witnessing significant growth, driven by increasing awareness and advancements in diagnostic techniques. One notable trend is the rising utilization of targeted therapies, such as Immunotherapy, which focuses on enhancing the body’s immune response against cancerous cells. For instance, the use of Pembrolizumab, a PD-1 inhibitor, has shown promise in clinical settings, offering new hope for patients with advanced EMPD who do not respond to traditional therapies. Furthermore, improved diagnostic methods, including biopsy and immunohistochemical staining, are facilitating earlier and more accurate identification of EMPD, leading to timely treatment interventions. As healthcare professionals become more familiar with the disease's clinical presentation, earlier diagnosis is expected to drive demand for innovative therapies. This trend enhances patient outcomes and creates opportunities for pharmaceutical companies to invest in the development of targeted treatment options, shaping the future of the EMPD market.
